Smoldering Myeloma Treatments

Below is a listing of treatments for smoldering 'asymptomatic' myeloma that are being tested in clinical trials around the US. We're here if you have questions or need help. Please call us today or create an account and we'll help you better understand your clinical trial options.

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

Daratumumab DARZALEX®

Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.

Learn more about this treatment


Nivolumab

Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Learn more about this treatment


Atezolizumab

Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.

Learn more about this treatment


Checkpoint Inhibitor

Immune checkpoint inhibitors are drugs – often made of antibodies – that unleash an immune system attack on cancer cells.

Learn more about these treatments


Carfilzomib KYPROLIS®

Carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is approved for use with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma in patients who have received one to three prior lines of therapy. Carfilzomib is injected into a vein through an IV.

Learn more about this treatment


Ixazomib NINLARO®

Ixazomib is an oral proteasome inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Learn more about this treatment


PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

Learn more about this treatment


Autologous Transplant

Autologous Transplant is a type of stem cell transplant that utilizes the patient's pre-collected own stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.

Learn more about this treatment


Monoclonal Antibody

Antibodies are cloned and used to attack one specific type of protein found in cancer cells.

Learn more about these treatments


Elotuzumab EMPLICITI®

Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.

Learn more about this treatment


Lenalidomide REVLIMID®

Lenalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is given as an oral medication.

Learn more about this treatment


Isatuximab

SAR650984 is a humanized IgG1 monoclonal antibody that binds to CD38+ cells, triggerring antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and tumor programmed cell death.

Learn more about this treatment


Pembrolizumab

One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.

Learn more about this treatment


Immunotherapy

Immunotherapy involves the use of many active agents such as cells, cytokines or vaccines (among others). These agents are used to induce, enhance or suppress the function of the immune system.

Learn more about these treatments


Ibrutinib

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.

Learn more about this treatment


Bruton's Tyrosine Kinase (BTK) Inhibitor

Brutons Tyrosine Kinase Inhibitors can block the cancer cell from growing and dividing by stopping messages from being passed by chemicals within the cell.

Learn more about these treatments


Vaccines

Cancer vaccines are designed to stimulate an immune response against tumor-specific or tumor-associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Learn more about these treatments


Immunomodulatory Drugs (IMID)

Immunomodulatory therapies typically involve special chemicals called cytokines. These therapies are designed to enhance the immune system to fight cancer.

Learn more about these treatments


Durvalumab

Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to strengthen the patient's immune system and attack the cancer.

Learn more about this treatment


Proteasome Inhibitor

Proteasome Inhibitors can block cancer cells from removing defective proteins, which can lead to cell death.

Learn more about these treatments

;